Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events

Abstract

This analysis represents the first investigation of early clinical outcomes in a small cohort of Canadian patients treated with ixekizumab. Overall, complete and rapid skin clearance was observed. Future studies including more patients and longer follow-up time are crucial to confirm these findings.